Dr. Bardoni on the Importance of the LIBRETTO-001 Trial With Selpercatinib in RET+ NSCLC

Video

Rodolfo Bordoni, MD, discusses the importance of the phase 1/2 LIBRETTO-001 trial with selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

Rodolfo Bordoni, MD, a medical oncologist, and director of research at Georgia Cancer Specialists, discusses the importance of the phase 1/2 LIBRETTO-001 trial (NCT03157128) with selpercatinib (Retevmo) in patients with RET fusion–positive non–small cell lung cancer (NSCLC).

Findings from the trial were impressive for 2 reasons, according to Bardoni. First, the trial marks the first time in which a specific inhibitor of RET fusion, selpercatinib, was utilized for patients with lung cancer, thyroid cancer, and other conditions that may carry a RET aberration, Bardoni says. Previous targeted therapies that were being used in this population were not specific inhibitors, which led to a limited efficacy. Additionally, these older agents were limited in both the patients who responded to treatment, as well as in those who experienced a prolonged response and clinical benefit, he explains. 

Secondly, the previous targeted agents were multitarget, and targeted different angiogenic gene products. Due to this, the agents caused a significant number of adverse effects, Bardoni concludes.

Related Videos
Arya Amini, MD
Vlad Gabriel Zaha, MD, PhD
Raj Singh, MD
Bruna Pellini, MD
Benjamin Levy, MD
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Jobelle Baldonado, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic